MELK inhibitor safety study for advanced breast cancer
Part of Cancer, Skin clinical trials.
This Phase 1 study tests how safe a drug called an MELK inhibitor is in people with advanced breast cancer that has spread or cannot be removed with surgery. If you qualify, the study is focused on side effects and includes a special group for triple-negative breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman, age 18 or older, and able to sign consent
- You must have breast cancer that is advanced or metastatic (has spread)
- Your cancer must be returned after prior treatment or there is no standard treatment, and it cannot be removed with surgery
- Your health status must be good enough for treatment (ECOG performance 0–1) and you must have at least 3 months to live
- Recent chemo and/or radiation side effects must be mostly gone (to grade 1 or lower, except mild/controlled nerve symptoms)
- You must be able to use reliable birth control during the study and for 3 months after the last dose (or you cannot get pregnant)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This study tests whether combining two new drugs (AK146D1 and AK112) can help people with advanced breast cancer that is HER2-negative (a type that doesn't have too much of a specific growth protein). The goal is to see if this combination can shrink tumors and improve survival.
This study tests a new drug called KM257 for people with advanced solid tumors that have a high level of a protein called HER2. The drug is given as an infusion and is designed to target cancer cells with this protein, potentially slowing or stopping tumor growth.
This trial tests an experimental drug called KM602 for people with advanced solid tumors that have stopped responding to standard treatments, particularly melanoma and non-small cell lung cancer. It aims to see if the drug is safe and effective in shrinking or controlling tumors.
This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer. The goal is to find the best dose and see if the combination is safe and helpful.
Hear when a new Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.